首页> 外文期刊>Current medical research and opinion >Evaluating clinically meaningful change on the ITP-PAQ: preliminary estimates of minimal important differences.
【24h】

Evaluating clinically meaningful change on the ITP-PAQ: preliminary estimates of minimal important differences.

机译:在ITP-PAQ上评估具有临床意义的变化:最小重要差异的初步估计。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVE: Interpretation of data from health-related quality of life (HRQoL) questionnaires can be enhanced with the availability of minimally important difference (MID) estimates. This information will aid clinicians in interpreting HRQoL differences within patients over time and between treatment groups. The Immune Thrombocytopenic Purpura (ITP)-Patient Assessment Questionnaire (PAQ) is the only comprehensive HRQoL questionnaire available for adults with ITP. RESEARCH DESIGN AND METHODS: Forty centers from within the US and Europe enrolled ITP patients into one of two multicenter, randomized, placebo-controlled, double-blind, 6-month, phase III clinical trials of romiplostim. Patients enrolled in these studies self-administered the ITP-PAQ and two items assessing global change (anchors) at baseline and weeks 4, 12, and 24. Using data from the ITP-PAQ and these two anchors, an anchor-based estimate was computed and combined with the standard error of measurement and standard deviation to compute a distribution-based estimate in order to provide an MID range for each of the 11 scales of the ITP-PAQ. RESULTS: A total of 125 patients participated in these clinical trials and provided data for use in these analyses. Combining results from anchor- and distribution-based approaches, MID values were computed for 9 of the 11 scales. MIDs ranged from 8 to 12 points for Symptoms, Bother, Psychological, Overall QOL, Social Activity, Menstrual Symptoms, and Fertility, while the range was 10 to 15 points for the Fatigue and Activity scales of the ITP-PAQ. These estimates, while slightly higher than other published MID estimates, were consistent with moderate effect sizes. CONCLUSIONS: These MID estimates will serve as a useful tool to researchers and clinicians using the ITP-PAQ, providing guidance for interpretation of baseline scores as well as changes in ITP-PAQ scores over time. Additional work should be done to finalize these initial estimates using more appropriate anchors that correlate more highly with the ITP-PAQ scales.
机译:目的:通过提供最小重要差异(MID)估计值,可以增强对与健康相关的生活质量(HRQoL)调查表的数据的解释。该信息将帮助临床医生解释患者内部以及治疗组之间的HRQoL差异。免疫性血小板减少性紫癜(ITP)患者评估问卷(PAQ)是唯一可用于ITP成人的综合性HRQoL调查表。研究设计和方法:来自美国和欧洲的40个中心将ITP患者纳入了romiplostim的两个多中心,随机,安慰剂对照,双盲,6个月,III期临床试验之一。参加这些研究的患者自行管理了ITP-PAQ,并在基线以及第4、12和24周评估了两项评估整体变化(锚点)的项目。使用ITP-PAQ和这两个锚点的数据,可以得出基于锚点的估计值。计算并与测量的标准误差和标准偏差相结合,以计算基于分布的估计值,以便为ITP-PAQ的11个标度中的每一个提供MID范围。结果:总共125名患者参加了这些临床试验,并提供了用于这些分析的数据。结合基于锚和分布的方法的结果,为11个量表中的9个量表计算了MID值。症状,烦恼,心理,总体生活质量,社交活动,月经症状和生育力的MID范围为8到12点,而ITP-PAQ的疲劳和活动量表的MID范围为10到15点。这些估计数虽然比其他已公布的MID估计数略高,但与中等效应大小一致。结论:这些MID估计值将为使用ITP-PAQ的研究人员和临床医生提供有用的工具,为解释基线评分以及随时间变化的ITP-PAQ评分提供指导。应该做更多的工作来使用更合适的锚来最终确定这些初始估计,这些锚与ITP-PAQ量表的相关程度更高。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号